顺铂处理后剪接因子SRSF12 mRNA异构体在多种细胞中的变化  

Changes of Alternative Splice Variant of the SRSF12 by Cisplatin in Multiple Cells

作　　者：马春霞[1] 李明阳[1] 吴瀚欣 杨渊[1] 杨梦莉[1] 俞建昆[1] MA Chun-xia;LI Ming-yang;WU Han-xin;YANG Yuan;YANG Meng-li;YU Jian-kun(The Institute of Medical Biology Chinese Academy of Medical Sciences驭Peking Union Medical College,Yunnan Key Laboratory of Vaccine ResearchDevelopment on Severe Infections Disease,Kunming Yunnan 650118;Kunming Medical University,Kunming Yunnan 650500,China)

机构地区：[1]中国医学科学院医学生物学研究所,云南昆明650118 [2]昆明医科大学,云南昆明650500

出　　处：《昆明医科大学学报》2018年第1期5-9,共5页Journal of Kunming Medical University

基　　金：中国医学科学院医学与健康科技创新工程重大协同创新基金资助项目(2016-12M-2-001);国家自然科学基金资助项目(31570918)

摘　　要：目的用梯度浓度顺铂处理多种细胞后检测剪接因子SRSF12的mRNA异构体并分析其变化.方法用梯度浓度顺铂处理肺癌细胞A549和H1299、人胚肾细胞293FT以及宫颈癌细胞系Si Ha、Ca Ski、C33A细胞后提取总RNA,利用半定量RT-PCR检测分析SRSF12基因mRNA异构体及相对水平的变化.结果在除Caski细胞外的5种细胞中检测到了2种异构体(Isoform-a、b),且随着处理顺铂浓度的增加,Isoform-a的比例有增加趋势,Isoform-b的比例变化在A549及293FT细胞中变化不明显,在H1299及C33A细胞中渐弱,在Siha细胞中表达较弱且2种异构体均有渐弱趋势.结论在顺铂处理后,SRSF12的表达不仅具有组织特异性还具有细胞特异性.Objective To detect the changes of mRNA isoforms in multiple cancer cell lines with dose of cisplatin.Methods Total RNA of the cells treated by cisplatin were abstracted 24 h after the treatment.mRNA isoforms of SRSF12 gene were detected by semiquantitative RT-PCR.The ratios of mRNA isoforms were analyzed by gel image software and statistical analysis.Results Under the cisplatin treatment,2 mRNA isoforms of SRSF12 were detected in five cells except Caski cells,their ratios and relative mRNA levels were changed.With the increase of dose of cisplatin,the ratio of isoform-a was slightly increased;but the ratio of isoform-b was different,the changes were not obvious in the A549 and 293FT cells,the weaker expression was expressed in the H1299 and C33A cells,and the two isoforms were gradually weakening in the Siha cells.Conclution Under the cisplatin treatment in multiple cancer cells,the expression of SRSF12 shows tissue-specific and cell type-specific patterns.

关 键 词：顺铂 SRSF12 mRNA选择性剪接 组织特异性 细胞特异性 

分 类 号：R73-3[医药卫生—肿瘤]